Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market open
8 174,18 pts
+0.34%


Last updated : 19/11/2026 - 12h30
🏠 Home   ➤    Stock news

Nanobiotix shares among the leaders of the SBF 120, but down 12.9% over the week

The Parisian oncology nanomedicine biotech rebounds sharply at midday, in a Paris market slightly higher. This recovery follows a week of marked decline, right after two meetings between management and the financial community in London.


Nanobiotix shares among the leaders of the SBF 120, but down 12.9% over the week

A rebound that recovers only part of the weekly decline

Nanobiotix shares gain 5.15% to €25.32, placing them second in the SBF 120, behind Soitec, while the index advances 0.34%. The stock nevertheless remains below its three moving averages: the MM20 is at €27.45, a gap of 7.76% with the price, and the MM200 at €29.88.

Over one week, the stock still falls 12.93%, so the gain of the day mitigates this decline without erasing it. Over one month, by contrast, it retains a gain of 32.43%, earned during the sharp recovery in the first half of November.

A listing on two markets and cash announced through 2029

Nanobiotix is a single company listed on two markets: the ordinary share on Euronext Paris and the ADS on Nasdaq, at a ratio of one ADS for one share. The two lines mainly move on the same day, and only the Parisian line is eligible for the PEA.

On the fundamentals, first-half 2026 results, published on September 24, reported cash of €110.9 million, described as sufficient to finance operations through 2029.

The group is developing the radioamplifier NBTXR3 (JNJ-1900) with Johnson & Johnson. The latest clinical data date back to the ESMO congress of October 24, with a median overall survival of 17.8 months in anti-PD-1-resistant melanoma. The stock now trades between its support at €18.85 and its resistance at €30.36.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 3,6 millions d'euros
  • Quarterly revenue: 3,6 millions d'euros
  • Net income: -34,3 millions d'euros
Guidance from the release
  • « la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours